

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/20, 47/02	A1	(11) International Publication Number: WO 96/22082 (43) International Publication Date: 25 July 1996 (25.07.96)
<p>(21) International Application Number: PCT/GB96/00111</p> <p>(22) International Filing Date: 19 January 1996 (19.01.96)</p> <p>(30) Priority Data: 9501127.6 20 January 1995 (20.01.95) GB</p> <p>(71) Applicant (for all designated States except US): THE WELL-COME FOUNDATION LIMITED [GB/GB]; Unicom House, 160 Euston Road, London NW1 2BP (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): CARTER, Barry, Howard [US/US]; P.O. Box 6155, Kinston, NC 28501 (US). TILL-MAN, Lloyd, Gary [US/US]; Apartment 1, 816 Gallop Hill Road, Gaithersburg, MD 20879 (US).</p> <p>(74) Agent: McMUNN, Watson, P.; W.H. Beck, Greener & Co., 7 Stone Buildings, Lincoln's Inn, London WC2A 3SZ (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: VALACICLOVIR TABLETS CONTAINING COLLOIDAL SILICON DIOXIDE</p> <p>(57) Abstract</p> <p>A tablet comprising of at least 50 % w/w valaciclovir, and 0.05 to 3 % w/w colloidal silicon dioxide is provided which has excellent hardness and friability properties while still maintaining good lubrication of the tablet granules.</p>		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

VALACICLOVIR TABLETS CONTAINING COLLOIDAL SILICON DIOXIDE

5 This invention relates to a tablet of the antiviral drug valaciclovir.

10 The compound 9-[(2-hydroxyethoxy)methyl]guanine, otherwise known as acyclovir possesses potent antiviral activity and is widely used in the treatment and prophylaxis of viral infections in humans, particularly infections caused by the herpes group of viruses (see, for example, Schaeffer et al, Nature, 272, 583-585 (1978), UK Patent No. 1523865, US Patent No. 4,199,574). However, acyclovir is poorly absorbed from
15 the gastrointestinal tract upon oral administration and this low bioavailability means that multiple high doses of oral drug may need to be administered, especially for the treatment of less sensitive viruses or infections in order to achieve and maintain effective anti-viral levels in the plasma.

20 The L-valine ester of acyclovir (2-[2-amino-1,6-dihydro-6-oxo-purin-9yl)methoxy]ethyl L-valinate (herein referred to as valaciclovir) has been shown to possess much improved bioavailability whilst retaining the anti-viral properties of
25 acyclovir. A preferred form of this compound is its hydrochloride salt which is herein referred to as valaciclovir hydrochloride. Valaciclovir and its salts including the hydrochloride salt are disclosed in US Patent No. 4,957,924 (see particular example 1B), European Patent No. 0308065 (see
30 particularly example 1B) and Beauchamp et al, Antiviral Chemistry and Chemotherapy, 3(3), 157-164 (1992) (see particularly page 162 column 1). Tablets of valaciclovir are also generally disclosed in the US Patent No. 4,957,924 and European Patent No. 0308065.

-2-

During development of a tablet formulation containing a high proportion of valaciclovir, we often encountered difficulties in obtaining tablets of sufficient hardness and friability for pharmaceutical handling and for film coating.

5

If the tablet is too friable, it will chip or break during packaging and transport. The US Pharmacopoeia (USP) no. 23, 1995, p1981 at monograph 1216 requires that pharmaceutical tablets have a friability not exceeding 1%. If the tablet is too soft, it will crumble during, tumbling in the film coating pan.

10

In the reference manual 'Problem Solver' (compiled by FMC Corporation) at pages 8 and 9, the remedies for low tablet hardness are given *inter alia* as increasing the compression force applied to form the tablet, or decreasing the proportion of lubricant in the tablet formulation.

15

We tried to increase the hardness and friability of valaciclovir tablets by increasing the compression force, by decreasing the proportion of lubricant and increasing the proportion of binder, but found in each case that a sufficiently hard and non-friable tablet could not be produced in a practical way.

20

25

Furthermore, cracks were found in some tablets as a result of increasing the compression force. Additionally, valaciclovir has 'adhesive' properties in that it can stick to tablet dies and therefore needs to be efficiently lubricated. It is difficult therefore to reduce the proportion of lubricant without causing the tablets to stick. Furthermore, the disintegration time of the valaciclovir tablet is also quite long and therefore any possible solution to the hardness and friability problem could not have a substantial deleterious effect on either the disintegration time or lubrication (as measured by the ejection force) of the tablet formulation.

30

35

-3-

It is therefore an object of the invention to provide a robust tablet formulation of valaciclovir and salts thereof which is capable of being film coated and consistently providing tablets having a friability not exceeding 1%, a hardness of
5 at least 9kP and an ejection force not exceeding 1000 Newtons (1 kN).

The hardness of the tablet should be such that it not only has an acceptable crushing force (as measured by the kP value),
10 but also that the tablet does not break during tumbling.

It is a further preferred object of the invention to provide a robust formulation which is capable of consistently providing tablets substantially free of cracks.
15

We have now found an effective method of overcoming both of the above friability and hardness problems which involves the use of colloidal silicon dioxide in the tablet formulation.

20 The Handbook of Pharmaceutical Excipients 1994 at p253-256 does not mention colloidal silicon dioxide as an agent to improve the hardness of tablets. Neither does The Theory and Practice of Industrial Pharmacy (third edition) by Lachman, Lleberman and Kanig, mention colloidal silicon dioxide for
25 such a use.

Accordingly in a first aspect of the invention there is provided a tablet comprising at least about 50% w/w valaciclovir or a salt thereof present within the granules of
30 the tablet, a filler, a binding agent, a lubricant, and about 0.05% to about 3% w/w colloidal silicon dioxide, the lubricant and colloidal silicon dioxide being present extragranularly, wherein the friability of the tablet does not exceed 1%, the hardness is at least 9kP and the ejection force does not
35 exceed 1000 Newtons.

A tablet of this formulation containing 0.05% to 3% w/w silicon dioxide colloidal is robust, and has a substantially improved friability and hardness. Furthermore such improved properties is achieved while still retaining a satisfactory
5 disintegration time and lubrication properties, even when the formulation is blended under high shear. An excellent tablet providing acyclovir in a highly bioavailable form is thus provided by virtue of the invention.

10 Preferably the disintegration time of the tablet is not more than about 30 minutes, more preferably not more than about 25 minutes, and most preferably not more than about 20 minutes.

The ejection force should not be more than about 1000N,
15 preferably not more than about 800N, more preferably still not more than about 500N for tablets compressed at about 10 to 30 kN, preferably 10 to 20 kN.

Valaciclovir or a salt thereof are hereinafter referred to
20 generally as the 'active ingredient'.

The 1994 U.S. Pharmacopoeia describes colloidal silicon dioxide (in its monograph) as: a submicroscopic fumed silica prepared by the vapour phase hydrolysis of a silica compound.

25 Preferably the colloidal silicon dioxide is present in amounts of about 0.05% to about 1% w/w of the total formulation, more preferably at about 0.1% to about 1% w/w, and most preferably about 0.1% to about 0.5% w/w. We have found Aerosil (trade
30 mark) and Cab-o-sil (trade mark) to be very suitable.

The content of drug in the tablet is at least about 50% w/w, preferably about 60% w/w to about 90% w/w, more preferably still about 65% w/w to about 85% w/w and most preferably about
35 80% w/w. Preferably the (tapped) bulk density of the drug is about 0.1 to 0.9 g/cc, more preferably 0.3 to 0.7 g/cc, more

-5-

preferably still 0.34 to 0.66 g/cc, and most preferably 0.4 to 0.6g/cc. Suitably the drug is valaciclovir hydrochloride, preferably being of an anhydrous crystalline form including substantially a d-spacing pattern (derived from X-ray powder diffraction) as follows:

d spacing pattern (in Angstroms):

10.20 \pm 0.08, 8.10 \pm 0.06, 7.27 \pm 0.06, 6.08 \pm 0.05, 5.83 \pm 0.03, 5.37 \pm 0.02, 5.23 \pm 0.02, 4.89 \pm 0.02, 4.42 \pm 0.02, 4.06 \pm 0.02, 3.71 \pm 0.02, 3.39 \pm 0.02, 3.32 \pm 0.02, 2.91 \pm 0.02, 2.77 \pm 0.02.

Hereinafter by "anhydrous crystalline form" according to the invention, we mean a crystalline form having substantially the same X-ray powder diffraction pattern as shown in figures 1 to 3, or having substantially the same d spacing pattern as defined above.

Preferably the crystal form purity in any such drug lot of anhydrous crystalline valaciclovir hydrochloride used for valaciclovir tablets is at least 70%, more preferably at least 80%, more preferably still at least 90% and most preferably at least 95% anhydrous crystalline valaciclovir hydrochloride (as characterised above).

In an alternative method for measuring crystal form purity, since the anhydrous crystalline form of valaciclovir hydrochloride contains substantially no water of hydration, the level of other hydrated forms of valaciclovir hydrochloride in any drug lot used for tablets can be measured by the water of hydration content. Preferably any such drug lot of anhydrous crystalline valaciclovir hydrochloride contains no more than 3% w/w, more preferably no more than 2% w/w, more preferably still not more than 1 % w/w and most preferably not more than 0.5 % w/w water of hydration.

This water of hydration content is measured by the Karl Fischer method which is well known in the art and is described in the 1990 U.S. Pharmacopoeia at pages 1619-1621, and the European Pharmacopoeia, second edition (1992), part 2, sixteenth fascicule at v. 3.5.6-1.

Advantageously the filler is a cellulosic filler and is at least partly present extragranularly, which mitigates stress cracking of the tablet. A tablet formulation of the invention including colloidal silicon dioxide and extragranular cellulosic filler (such as microcrystalline cellulose) appears to have a synergistic effect and is particularly good and robust in that tablets of valaciclovir can consistently be made to an acceptable hardness without introducing stress cracks even under a high compression force.

According to a preferred aspect of the invention there is provided a tablet comprising at least 50% w/w valaciclovir or a salt thereof, a binding agent, a lubricant, 0.05 to 3% w/w colloidal silicon dioxide, and 3 to 30% of a cellulosic filler; wherein the valaciclovir or salt thereof is present within the granules of the tablet, the lubricant, colloidal silicon dioxide, and at least a portion of the cellulosic filler is present extragranularly; wherein the friability of the tablet does not exceed 1%, the hardness is at least 9kP, and the ejection force does not exceed 1000N.

Preferably the cellulosic filler is microcrystalline cellulose (e.g. Avicel); and is preferably present at 5 to 15% w/w, most preferably about 10% w/w. The particle size of the cellulosic filler is preferably 20 to 300 μ , more preferably 30 to 200 μ , and most preferably 50 to 100 μ .

According to a further aspect of the invention there is provided a tablet comprising at least 50% w/w valaciclovir or a salt thereof, a binding agent, a lubricant, and about 3% to

-7-

30% w/w of a cellulosic filler, the valaciclovir or its salt being present within the granules of the tablet and the lubricant and cellulosic filler being present extragranularly.

5

The binding agent serves, for example, to bind the primary and secondary particles together and improve tablet hardness. Preferably the binding agent is present in an amount of about 1% to about 5% w/w, more preferably at about 2% to about 4%
10 w/w, and is suitably a non-starch based binder such as methylcellulose or most preferably povidone. The grade of povidone is advantageously K30 and most preferably K90.

The binding agent such as the povidone, can be dissolved in
15 the granulating solvent (such as water) before adding to the drug, but preferably it is added (at least partly) dry to the drug and other excipients and then the granulating solution (such as povidone in water) added.

20 The lubricant is suitably present in an amount of about 0.1% to about 2.0% w/w, preferably about 0.1% to about 1.0% w/w. Although lubricants such as talc or sodium lauryl sulphate are suitable, preferably the lubricant is a stearate derivative, more preferably an alkali metal stearate, such as magnesium
25 stearate. The above amounts apply to the stearate, and they are ideally present in amount of at about 0.3% to about 0.6% w/w.

Although valaciclovir is very soluble, especially in its salt
30 form, it is preferable if a disintegrating agent is present in the tablet formulation, suitably in an amount of about 0.5% to about 20% w/w, more preferably at about 0.5% to 7.0% w/w. The disintegrating agent is advantageously present within the granules of the tablet and can be added before or after the
35 binding, agent. Clays such as kaolin, bentonite or veegum (trademark), and celluloses such as microcrystalline cellulose

or croscarmellose sodium e.g. Ac-Di-Sol (trademark) maybe used as disintegrants. Preferably a non-ionic disintegrant such as crospovidone is used. Preferably, the crospovidone is present at about 0.5% to about 7.0% w/w, more preferably about 2 to about 5% w/w, and preferably a portion is present intragranularly.

A further aspect of the invention provides a process for preparing a tablet comprising at least about 50% w/w valaciclovir or a salt thereof, a binding agent, a filler, a lubricant, and about 0.05 to 3.0% w/w colloidal silicon dioxide; wherein the hardness of the tablet is at least 9 kp, the friability is not more than 1%, and the ejection force is not more than 1000N; said process comprising forming granules which include valaciclovir or a salt thereof and then blending the lubricant and colloidal silicon dioxide with said granules.

Preferably said process comprises forming granules by mixing said valaciclovir or salt, optionally a binding agent or a portion thereof, and optionally the filler or a portion thereof; granulating with a granulating solution to form granules or dissolving the binding agent or a portion in the granulating solution before adding to valaciclovir; drying the granules; blending the granules with the lubricant, colloidal silicon dioxide, and optional filler or a portion thereof; and then compressing the blended mixture to form a tablet.

A preferred aspect of the invention provides a process for preparing a tablet comprising at least 50% w/w valaciclovir or a salt thereof, a binding agent, a lubricant, 0.05 to 3% w/w colloidal silicon dioxide, and 3 to 30% w/w of a cellulosic filler; wherein the hardness of the tablet is at least 9kP, the friability is not more than 1%, and the ejection force is not more than 1000N; said process comprising forming granules by mixing the valaciclovir or salt, optional

-9-

binding agent or a portion thereof, and optionally a portion of cellulosic filler; granulating with a granulating solution to form granules or dissolving the binding agent or a portion thereof in the granulating solution before adding to
5 valaciclovir; drying the granules; blending the granules with the lubricant, colloidal silicon dioxide, and at least a portion of the cellulosic filler; and then compressing the blended mixture to form a tablet.

10 The colloidal silicon dioxide can be first blended with the lubricant, preferably a stearate derivative (e.g. magnesium stearate) before blending with the granules or it can be added separately from the lubricant. When the lubricant is a
15 colloidal silicon dioxide is about 1:1 to 10:1, more preferable about 1: 1 to about 3: 1.

The present invention also provides a tablet (as described above) for use in medical therapy, e.g. in the treatment of
20 a viral disease in an animal, e.g. a mammal such as a human. The compound is especially useful for the treatment of diseases caused by various DNA viruses , such as herpes infections, for example, herpes simplex 1 and 2, varicella zoster, cytomegalovirus, Epstein-Barr viruses or human herpes
25 virus-6 (HHV-6) as well as diseases caused by hepatitis B. The active compound can also be used for the treatment of papilloma or wart virus infections and, may furthermore be administered in combination with other therapeutic agents, for
30 example with zidovudine, to treat retroviral associated infections in particular HIV infections.

In addition to its use in human medical therapy, the active compound can be administered to other animals for treatment of viral diseases, e.g. to other mammals.

-10-

The present tablet also provides a method for the treatment of a viral infection, particularly a herpes viral infection, in an animal, e.g. a mammal such as a human, which comprises administering to the host one or more tablets of the invention to provide an effective antiviral amount of the active compound.

The present invention also provides the use of the active compound in the preparation of a tablet of the invention for the treatment of a viral infection.

A tablet of the invention may be administered by any route appropriate to the condition to be treated, but the preferred route of administration is oral. Although tablets generally are included within the scope of the invention, for example a dispersible tablet or chewable tablet, preferably the tablet is a swallowable tablet, most preferably a film-coated swallowable tablet. It will be appreciated however, that the preferred route may vary with, for example, the condition of the recipient.

For each of the above-indicated utilities and indications the amounts required of the active ingredient (as above defined) will depend upon a number of factors including the severity of the condition to be treated and the identity of the recipient and will ultimately be at the discretion of the attendant physician or veterinarian. In general however, for each of these utilities and indications, a suitable effective dose will be in the range 1 to 150 mg per kilogram bodyweight of recipient per day, preferably in the range 5 to 120 mg per kilogram bodyweight per day (Unless otherwise indicated, all weights of the active ingredient are calculated with respect to the free base valaciclovir). The desired dose is preferably presented as one, two, three or four or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage

forms, for example, containing about 50 to 2000 mg, preferably about 250, 500, 1000 or 2000mg of active ingredient per unit dose form.

- 5 The following dosage regimes are given for guidance:
treatment of herpes simplex virus types 1 and 2 infection:-
total daily dose of about 1 or 2g administered at 500mg twice
a day or 1g twice a day for 5 to 10 days; suppression of
herpes simplex virus types 1 and 2 infections:- total daily
10 dose about 250mg to 1g for about one to ten years (depending
on the patient);
treatment of varicella zoster virus infections (for example
shingles):- daily dose about 3g administered at 1g three
times a day for seven days; suppression of cytomegalovirus
15 infections:- total daily dose about 8g administered at 2g 4
times a day. For transplant patients this daily dose is
administered for three to six months for the period at
risk; and for HIV positive patients said daily dose is
administered as usually indicated for improving quality of
20 life, for example for two years or more.

Early results now indicate that valaciclovir can be used in
the effective suppression of recurrent genital herpes at a
once daily dose of from about 200 mg to about 1000 mg for
25 an effective treatment period. The most likely daily
dosages are 250 mg, 500 mg or 1000 mg.

Valaciclovir hydrochloride was made as described below:

Example 1

- 30 A. 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)
methoxy]ethyl-N-[(benzoxycarbonyl)-L-valinate
CBZ-L-valine (170 g) was dissolved in dimethylformamide
(DMF) (750 ml) and cooled. A cold solution of N,N-dicyclo-
hexyl-carbodiimide (DCC) (156.7 g) in DMF (266 ml) was
35 added and stirred with cooling. Acyclovir (10.1 g) was
added in a single portion, and then 4-(dimethylamino)
pyridine (9.4 g) was added while maintaining cooling. The
mixture was stirred cold overnight. A white

-12-

precipitate of the by-product was then removed by filtration. The filtrate was reduced in volume by vacuum distillation and the concentrate treated with water (663 ml) then heated to 70°C. The suspension was cooled to
5 20°C, filtered and the solid washed with water.

The damp, crude material was then purified by recrystallisation from denatured alcohol (1.2 litres) to afford the title compound as a damp white crystalline solid
10 (281.5 g).

B. 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxy]ethyl-L-valinate hydrochloride

15 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl-N-[(benzyloxy)carbonyl]-L-valinate (175 g) was charged to aqueous denatured alcohol (335 ml/795 ml) and heated to reflux. The solution was then cooled to 40°C. The suspension was treated with 5% palladium on carbon catalyst
20 (35 g wet weight 50% wet with water) then formic acid (30.6 ml of 90% w/w) added over 1 hour. The reaction mixture was stirred for a further 1 hour then a second charge of formic acid made (19.5 ml) and the mixture filtered to remove the catalyst. The filter cake was washed with denatured
25 alcohol and the combined filtrates were treated with concentrated hydrochloric acid (33.7 ml) and the resultant mixture was concentrated by vacuum distillation.

Acetone (1295 ml) was then added over 15 minutes and the
30 suspension stirred for 1 hour before filtering off the product. The solid was then slurried with acetone (circa. 530 ml), refiltered and dried at 60°C in vacuo to give the title compound (1123 g : 81.6%).

35 A 15 g sample of this material was combined with denatured alcohol (circa. 7 ml), to moisten and was heated with

-13-

agitation at 60°C overnight in a closed flask to avoid loss of alcohol and maintain the dampness of the mixture. The mixture was then dried at 60°C *in vacuo* to afford the product as the desired morphic form.

5

Physical Data:

Karl Fischer value : 0.9% w/w water.

- 10 The X-ray powder diffraction patterns of the product of example 1B are shown in Figure 1 of the accompanying drawings.
- The d spacings and further X-ray diffraction data are shown in Table 1.

15

-14-

Table 1

	Peak No: I/I _{max} (%)	Angle (degrees)	Peak (counts)	d Spacing pattern (Å)	Error in d (± Å)	
5	1	3.56	680	24.8	0.5	24
10	2	8.62	1151	10.25	0.08	39
	3	9.42	87	9.38	0.07	3
	4	10.86	1438	8.14	0.06	49
	5	12.10	835	7.31	0.06	28
15	6	13.22	198	6.69	0.05	6
	7	14.49	2172	6.11	0.05	75
	8	15.12	455	5.85	0.03	15
	9	15.90	352	5.57	0.02	12
	10	16.45	1969	5.38	0.02	68
20	11	16.90	744	5.24	0.02	25
	12	17.33	119	5.11	0.02	4
	13	18.12	1013	4.89	0.02	35
	14	22.71	1429	4.43	0.02	49
	15	20.55	256	4.32	0.02	8
25	16	21.21	370	4.19	0.02	12
	17	21.83	753	4.07	0.02	26
	18	22.71	95	3.91	0.02	3
	19	23.95	2893	3.71	0.02	100
	20	25.10	171	3.54	0.02	5
30	21	26.21	1784	3.40	0.02	61
	22	26.89	428	3.31	0.02	14
	23	27.08	373	3.29	0.02	12
	24	28.02	158	3.18	0.02	5
	25	28.27	161	3.15	0.02	5
35	26	28.91	391	3.09	0.02	13
	27	29.68	191	3.01	0.02	6
	28	30.55	502	2.92	0.02	17
	29	31.34	110	2.85	0.02	3
	30	31.58	98	2.83	0.02	3
40	31	32.13	597	2.78	0.02	20
	32	32.96	260	2.72	0.02	8
	33	33.99	344	2.64	0.02	11
	34	34.38	374	2.61	0.02	12
	35	35.12	141	2.55	0.02	4
45	36	36.78	408	2.44	0.02	14
	37	38.71	101	2.32	0.02	3

$$I/I_{\max} = (\text{peak height}/\text{max. peak ht}) \times 100$$

-15-

The powder sample used to produce the above X-ray diffraction data was prepared by an equivalent method as the powder sample used to produce the X-ray diffraction data of table 2 (described hereinafter) except that for the
5 above data the following preparation was used to prepare the powder sample.

The sample was prepared by milling 1 g of sample in a plastic cup using two acrylic balls for 5 minutes with a
10 Chemplex Spectromill. The samples were then back packed against a glass slide to a depth of 2 mm.

The X-ray diffraction scan was obtained using a Scintag PADV diffractometer in the step scan mode at 0.02° per step
15 and a 10 second count per step. The sample holder was spun at 1 rotation per second during the scan. Additional setting as described below.

X-ray generator:	45 kV, 40 mA
20 Radiation:	Copper K alpha radiation
Fixed divergent slit:	1 mm
Incident scatter slit:	2 mm
Diffracted scatter slit:	0.5 mm
Receiving slit:	0.3 mm
25 Goniometer radius:	235 mm
Detector:	Scintillation with a graphite monochromator.

The peak intensities are reported as absolute counts of the peak top. The intensity units on the X-ray diffraction
30 plot are counts/sec. The absolute counts = counts/sec x count time = counts/sec x 10 sec. The peak intensities in the table have been corrected for background and copper K alpha II X-ray wavelength contribution.

Example 2

A. 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)
methoxyethyl-N-[(benzyloxy)carbonyl]-L-valinate

5 CBZ-L-valine (167 g) was dissolved in dimethylformamide (DMF) (750 ml) and cooled to 0.5°C. A cold solution of N,N-dicyclohexylcarbodiimide (DCC) (153.5 g) in DMF (266 ml) was added followed by acyclovir (111.7 g) in a single
10 portion. 4-(Dimethylamino)pyridine (9.4 g) was then added and the mixture stirred cold overnight. A white precipitate of the by-product was then removed by filtration. The solvent was partially removed by vacuum distillation and the concentrate treated with water (663
15 ml) then heated to 70°C. The suspension was cooled to 20°C, filtered and the solid washed with water.

The damp, crude material was then purified by recrystallisation from denatured alcohol (1.2 litres) to
20 afford the title compound as a damp white crystalline solid (215.3 g).

B. 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)
methoxyethyl-L-valinate hydrochloride

25 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl-N-[(benzyloxy)carbonyl]-L-valinate (200 g) was charged to aqueous denatured alcohol (382 ml / 908 ml) and heated to reflux to dissolve solids. The solution was cooled to
30 40°C. The suspension was treated with a 50% w/w paste of 5% palladium on carbon catalyst and water (40 g) then formic acid (96% w/w : 32.8 ml) added over 1 hour. The reaction mixture was stirred for a further 1 hour then a
35 second charge of formic acid made (20.88 ml) and the mixture filtered to remove the catalyst. The filtrate was

treated with concentrated hydrochloric acid (38.56 ml) and the resultant mixture was concentrated under vacuum.

- 5 Acetone (1480 ml) was then added over 15 minutes and the suspension stirred for 1 hour before filtering off the product. The solid was then slurried with acetone (ca. 500 ml), refiltered and dried at 60°C *in vacuo* to give the title compound (137.75 g : 87.6%).
- 10 A 10 g sample of this material was combined with denatured alcohol (3.5 ml), heated at 60°C for several hours and the solvent then removed *in vacuo* to afford the product as the desired morphic form.
- 15 Crystal Form Purity: the sample of example 2(B) contained above 90% of the anhydrous crystalline form valaciclovir.

20 The X-ray powder diffraction patterns of the product of example 2(B) are shown in Figures 2 and 3 of the accompanying drawings in which:-

Fig 2 is a linear plot X-ray diffractogram; and

25 Fig 3 is a square root plot X-ray diffractogram.

The d spacings and further X-ray diffraction data are shown in Table 2

Table 2

	Peak No:	Angle (degrees)	Peak (counts)	d Spacing pattern (Å)	I/I _{max} (%)
5					
	1	3.62	2673	24.40	35
	2	7.21	119	12.26	2
	3	8.64	1910	10.22	25
10	4	9.43	180	9.37	2
	5	10.86	2652	8.14	35
	6	12.12	734	7.30	10
	7	13.24	615	6.68	8
	8	13.77	106	6.42	1
15	9	14.50	2333	6.11	31
	10	15.14	635	5.85	8
	11	15.89	511	5.57	7
	12	16.44	2652	5.39	35
	13	16.90	1267	5.24	17
20	14	17.33	475	5.11	6
	15	18.13	1648	4.89	22
	16	20.05	2172	4.43	28
	17	20.56	640	4.32	8
	18	21.20	1096	4.19	14
25	19	21.78	2034	4.08	27
	20	21.90	1384	4.06	18
	21	22.66	729	3.92	10
	22	23.94	7621	3.71	100
	23	24.39	1624	3.65	21
30	24	25.11	967	3.54	13
	25	25.86	2460	3.44	32
	26	26.21	5127	3.40	67
	27	26.82	1892	3.32	25
	28	26.89	1927	3.31	25
35	29	27.19	1429	3.28	19
	30	27.99	1156	3.18	15
	31	28.35	1076	3.15	14
	32	28.87	1722	3.09	23
	33	28.94	1529	3.08	20
40	34	29.62	1274	3.01	17
	35	30.56	1673	2.92	22
	36	31.30	999	2.86	13
	37	32.25	2570	2.77	34
	38	33.04	1376	2.71	18
45	39	34.00	1806	2.63	24
	40	34.45	1225	2.60	16
	41	35.13	1149	2.55	15
	42	36.77	1600	2.44	21
	43	38.01	576	2.37	8
50	44	38.76	729	2.32	10
	45	39.52	524	2.28	7
	46	40.70	751	2.22	10

Table 2 Continued

	Peak No:	Angle (degrees)	Peak (counts)	d Spacing pattern (Å)	I/Imax (%)
5					
	47	41.28	870	2.19	11
	48	41.88	686	2.16	9
	49	42.47	718	2.13	9
10	50	43.40	548	2.08	7
	51	44.53	729	2.03	10

The diffraction patterns of the product of example 2B were generated on a Phillips PW1800 Automatic X-ray Powder
15 Diffractometer using a scan of 2 to 45 2 θ with step intervals of 0.02 degrees and an integration time of 4 seconds per step.

Generator settings: 40 KV, 45 mA, Cu alpha 1,2 wavelengths:
20 1.54060, 1.54439 Å; Step size, sample time: 0.020 deg, 4.00 s, 0.005 deg/s; monochromator used: yes; divergence slit: automatic (irradiated sample length: 10.0 mm); peak angle range: 2.000 - 45.000 deg; range in D spacing: 44.1372 - 2.01289 Å; peak position criterion: top of smoothed data;
25 cryst peak width range: 0.00 - 2.00 deg; minimum peak significance: 0.75 maximum intensity: 7621 cts, 1905.3 cps.

The powder sample was prepared as follows:

30 A 1 gram portion of valaciclovir hydrochloride was transferred to a Retsch 10 ml polystyrol container ref 31-762 containing 2 acrylic balls ref 26-253 and was then ground to a very fine powder using a Retsch MM2 miser mill set at 100% power for five minutes. The ground powder was
35 back loaded into a Philips PW1811/10 sample holder which had been placed inverted on a perfectly smooth surface (e.g. that afforded by a glass plate or a highly polished metal sheet). The powder was then packed into the holder and further powder added and packed until the holder was
40 full. A Philips PW 1811 00 bottom plate was then clamped

-20-

into the holder and the entire assembly was then inverted before removing the glass/metal plate in an upwards direction to reveal the smooth sample surface which was flush with that of the holder.

5

The invention is illustrated below in the following examples and the properties of the tablets show in table 3 hereafter.

10

Example	3				4				5			
	mg/ tablet	kg/ Batch	w/w	mg/ Tablet	kg/ Batch	w/w	mg/ Tablet	kg/ Batch	mg/ Tablet	kg/ Batch	w.w	
Core (intra granular):												
valaciclovir hydrochloride *2	576.5	0.9916	82.0	576.5	0.9916	82.8	576.5	0.9916	576.5	0.9916	82.3	
microcrystalline cellulose (Avicel PH101)	70.0	0.1204	10.1	70.0	0.1204	10.0	70.0	0.1204	70.0	0.1204	10.0	
crospovidone	28.0	0.04816	4.0	28.0	0.04816	4.0	28.0	0.04816	28.0	0.04816	4.0	
povidone K30												
povidone K90	22.0	0.03784	3.1	22.0	0.03784	3.2	22.0	0.03784	22.0	0.03784	3.1	
extragranular:												
micro ³ crystalline cellulose (Avicel PH101)	-	-	-	-	-	-	-	-	-	-	-	
crospovidone	-	-	-	-	-	-	-	-	-	-	-	
colloidal silicon dioxide (CAB-O-SIL M-5 [®])	2.0	0.00160	0.3	-	-	-	-	-	-	-	-	
magnesium stearate	4.0	0.0032	0.6	4.0	0.0032	0.6	4.0	0.0032	4.0	0.00320	0.6	
TOTAL WEIGHT	702.5	1.2028	100.0	696.5	1.198	100.0	700.5	1.2012	700.5	1.2012	100.0	

- 21a -

Example	6				7			
	mg/ Tablet	kg/ Batch	w/w	mg/ Tablet	kg/ Batch	w/w		
Ingredients								
Core (intra granular):								
valaciclovir hydrochloride *2	576.5	0.9973	82.3	576.5	0.9973	82.0		
microcrystalline cellulose (Avicel PH101)	-	-	-	-	-	-		
crospovidone	14.0	0.02422	2.0	14.0	0.02422	2.0		
povidone K30								
povidone K90	22.0	0.03806	3.1	22.0	0.03806	3.1		
extragranular:								
micro ³ crystalline cellulose (Avicel PH101)	70.0	0.05600	10.0	70.0	0.05600	10.0		
crospovidone	14.0	0.11200	2.0	14.0	0.01120	2.0		
colloidal silicon dioxide (CAB-O-SIL M-5 [®])	-	-	-	2.0	0.00160	0.3		
magnesium stearate	4.0	0.00320	0.6	4.0	0.00320	0.6		
TOTAL WEIGHT	700.5	1.12998	100.0	702.5	1.13158	100.0		

- * Bulk density 0.6g/cc after 50 taps (anhydrous crystalline form); Karl Fischer water content = 0.4.
1. Core weight per batch : 0.5572kg for examples 3, 4 and 5; 0.4900kg for examples 6 and 7.
 2. Factor 1.153 = 100
 3. Average particle size about 50 μ

Example	8		9	
	mg/ tablet	w/w	mg/ tablet	w/w
valaciclovir hydrochloride*	615	65.80	615	65.74
lactose	205	21.93	205	21.91
microcrystalline ¹ cellulose (Avicel PH101) (intragranular)	75	8.02	75	8.02
povidone K30	18	19.3	18	1.92
crospovidone (intragranular)	18	1.93	18	1.92
colloidal silicon dioxide (Aerosil 200)	0.0	0.0	0.69	0.10
magnesium stearate	3.6	0.39	3.6	0.38
TOTAL WEIGHT	934.6	100.0	935.5	100

* bulk density 0.45 g/cc after 50 taps (anhydrous crystalline form)

¹ Average particle size about 50 μ .

Example	10		11	
	mg/ tablet	w/w	mg/ tablet	w/w
valaciclovir hydrochloride*	580	81.01	580	82.60
5 lactose	-	-	-	-
microcrystalline cellulose² (Avicel PH101) (intragranular)	70	9.78	-	-
10 microcrystalline cellulose (extragranular)	-	-	70.4	10.03
povidone K30	35	4.89	-	-
15 povidone K90	-	-	21.7	3.09
crospovidone (intragranular)	28	3.91	12	1.71
crospovidone (extragranular)	-	-	14.1	2.01
20				
magnesium stearate	3.0	0.42	4.0	0.57
TOTAL WEIGHT	716	100.0	702.2	100.0

* bulk density 0.38 g/cc after 50 taps (anhydrous crystalline form)

25 1 Average particle size about 50 μ .

The tablets of the examples were made as disclosed below.

Examples 3 to 7

- 5 Step 1. The core ingredients were sifted with a 20 mesh
 hand screen, and then blended in an appropriately
 sized V-shell blender for 10 minutes.
- 10 Step 2. The blended powders from Step 1 were then
 granulated in a 10 litre high shear mixer (model-
 SP1) by adding pure water while mixing.
 Approximately 11-14% water, w/w of the core
 ingredients was then added and the mixture massed
 for 3 to 4½ minutes.
- 15 Step 3. The granule from Step 2 was dried in a tray
 (examples 5, 6 and 7) or vacuum (examples 3 and
 4) drier (model-SP1) at a temperature of 50°C to
20 an acceptable moisture content of approximately
 1.0 to 2.0 % L.O.D.
- 25 Step 4. The remaining ingredients were sifted through a
 20 mesh screen and added to the core ingredients
 of step 3, and then the mixture was sifted using
 a Comil Model 197 AS fitted with a 0.062" screen.
- Step 5. The mixture was then blended in an appropriately
 sized V-shell blender for 5 minutes.
- 30 Step 6 The blended granule from Step 5 was compressed on
 a Manesty Beta Press fitted with capsule shaped
 tooling, 18.25 mm x 7.14 mm, at a compression
 weight of approximately 700 mg and a compression
 force of about 14.5 to 18 kN.
- 35 Step 7 The tablets can then optionally be film coated by

-25-

using standard methods such as using white colour concentrate, methylhydroxypropylcellulose, titanium dioxide, polyethylene glycol and polysorbate.

5

Hardness (crushing force through the long axis) was measured using a Key hardness tester, Model HT-300.

10 Friability (percent weight loss after 100, six inch drops) was measured in accordance with the USP no. 23, 1995, p1981 at monograph 1216, using an Erweka friability tester, Model TA-3. Physical properties were measured at comparable compression forces. The disintegration time was measured in accordance with the monograph in USP 23 (1995) at page 1790.

15

Examples 8 and 9

Step 1. The following ingredients as shown were sifted with a hand screen.

20

30 Mesh

valaciclovir hydrochloride	5.289 kg
lactose	1.763 kg
microcrystalline Cellulose	0.6450 kg
povidone K30	0.1548 kg
25 crosopovidone	0.1548 kg

60 Mesh

magnesium stearate	0.03096 kg
colloidal silicon dioxide (CSD)	0.002598 kg

30 Step 2. The 30 mesh sifted ingredients from Step I were then blended, excluding the povidone, in a 1 cubic foot V-shell blender for 10 minutes.

35 Step 3. 1.540 kg of SD3A alcohol (ethanol denatured with 5% methanol) was then mixed with 0.6600 kg of purified water and the screened povidone, 0.1548

-26-

kg, was dissolved in 0.6192 kg of the mixed solvents by hand stirring.

5 Step 4. The blended powders from Step 2 were then granulated in a 1 cubic foot Littleford Lodge mixer by adding the dissolved povidone while mixing. 1.315 kg of more mixed solvent was added and the mixture massed for seven minutes total as shown below.

10 Ploughs 7 min Choppers 6.5 min

15 Step 5. The granule from Step 4 was then dried in a Fluid Bed Dryer (Glatt GPCG5) with an inlet air temperature of 50°C to any acceptable moisture content of approximately 1.0 to 3.0% L.O.D.

20 Step 6. The granule from Step 5 was then sifted using a Fitz Mill Model M fitted with a 30 mesh screen, with knives forward, operating at medium speed.

25 Step 7. The screened magnesium stearate from step 1 was added to the granule from Step 6 and blended for 5 minutes using the blender from Step 2. This was labelled as example 10 (2.650kg).

30 Step 8. Part of the blended granule from Step 7 was compressed on a Manesty Beta Press fitted with oval tooling, 19.1 mm x 10.2 mm, at a compression weight of approximately 934.6 mg.

35 Step 9. The remainder of the lubricated granule 2.650 kg (from Step 7) was weighed and the sifted CSD from step I added, then dispersed by hand and the mixture blended for 5 minutes in the blender from Step 3. This portion was labelled as Example 11. The mixture was compressed to form tablets.

Examples 10 and 11 were manufactured in a substantially similar manner to Examples 9 and 10 with the following exceptions.

- 5 1. All ingredients were sifted through a 20 mesh sieve.
2. Drug and intragranular ingredients were blended for 10 minutes.
3. The amounts of water and SD3A alcohol were
10 adjusted for the difference in batch size.
4. Dried granule was milled using a Comil Model 197AS with 0.062" screen.
5. Example 11 was dried in a tray drier.
- 15 6. The magnesium stearate was blended for 10 minutes after 10 minutes preblend of the milled granule and other ingredients.

TABLE 3

Example Numbers	Compression Force (kN)	Hardness (kP)	Friability (%)	Disintegration Time (mins)	Ejection Force (Newtons)	Stress Cracks (after heading ¹)
3a)	15.256	10.0	0.035	15.36	395	Yes
3b)	17.896	13.3	0.041	16.60	452	Yes
4	14.746	8.2 ³	0.107	13.94	305	Yes ²
5a)	15.343	9.9	0.15	17.95	300	Yes
5b)	17.956	12.5	0.10	19.96	329	Yes
6a)	15.658	11.9	0.15	18.04	306	Yes/faint
6b)	17.771	14.7	0.14	17.68	324	Yes
7a)	15.495	12.6	0.13	18.89	366	No
7b)	17.896	15.3	0.14	20.11	411	No
8a)	14.3	5.9	1.78	not available (N/A)	410	
8b)	31.4	9.7	1.70	N/A	450	
9a)	14.7	13.6	0.04	10.3	332	
9b)	30.7	22.8	0.03 ³	12.6	330	
10	Setting 6	14.4		N/A	B/A	Yes
11	Setting 7	15.5		N/A	N/A	No

1. Heated in a 50°C forced air oven to simulate film coating.
2. Stress cracks before and after heating.
3. One tablet broke in half (unacceptable hardness)

As can be seen from the results, the tablet of example 4 (which lacks colloidal silicon dioxide and has microcrystalline cellulose extragranularly) broke in half during tumbling, to simulate film coating conditions. The hardness of the tablet is therefore totally unacceptable. On the contrary, when colloidal silicon dioxide was added (example 3) the tablet surprisingly did not break and furthermore the disintegration time and ejection force increased by substantially less than would be expected.

The tablets of examples 5 and 6, like that of example 3, developed stress cracks after heating. In the tablet of example 3 there was present colloidal silicon dioxide and intragranular microcrystalline cellulose; in example 5 the microcrystalline cellulose was also intragranular, but there was no colloidal silicon dioxide; and in example 6 again there was no colloidal silicon dioxide, but the microcrystalline cellulose was extragranular. Surprisingly, however, when colloidal silicon dioxide is present and the microcrystalline cellulose is extragranular, there appears to be synergy which prevents stress cracking. This effect can be seen in the table of example 7 where there are no stress cracks, and furthermore the hardness and friability were good. As with the table of example 3, the disintegration and ejection force were increased substantially less than would be expected.

As can also be seen from comparative example 8a) the hardness value is very low and the friability fails the US Pharmacopoeia (USP) limit of 1%. Even at the very high compression force used in example 8b), the friability still fails the USP test.

In contrast on the addition of about 0.1% w/w of colloidal silicon dioxide (in example 9a and b), hardness and friability have dramatically improved. Furthermore the

-30-

ejection force, which was good before the addition of colloidal silicon dioxide is still good, and in fact actually improved on its addition. The disintegration time of the tablets of example 9 is also very satisfactory.

5

Additionally when the formulation of example 11 is repeated incorporating colloidal silicon dioxide in amounts ranging from 0.05 to 3% w/w, excellent tablets can be consistently produced having a high hardness and low friability value, substantially free of stress-cracks.

10

The robust tablet formulation of the invention therefore can consistently provide valaciclovir tablets having excellent handling characteristics which are suitable for film coating and which still have an adequate lubricating and disintegration time.

15

CLAIMS

1. A tablet comprising at least about 50% w/w
5 valaciclovir or a salt thereof, a filler, a binding
agent, a lubricant and about 0.05 to about 3% w/w
colloidal silicon dioxide wherein the valaciclovir
or a salt thereof is present within the granules of
the tablet, the lubricant and silicon dioxide being
10 present extragranularly; wherein the friability of
the tablet does not exceed 1%, the hardness is at
least 8 kP, and the ejection force does not exceed
1000 Newtons.
2. A tablet as claimed in any one of the preceding
15 claims wherein the colloidal silicon dioxide is
present in an amount of about 0.1% to about 0.5%
w/w.
3. A tablet as claimed in claims 1 or 2 wherein the
20 filler is present in an amount of about 3% w/w to
about 30% w/w.
4. A tablet as claimed in claim 3 wherein the filler
is and is present at about 5% to about 15% w/w.
25
5. A tablet as claimed in claim 4 wherein the filler
is a cellulosic filler.
6. A tablet as claimed in claims 4 or 5 wherein the
30 cellulosic filler is at least partly present
extragranularly.
7. A tablet as claimed in Claims 5 or 6, wherein the
35 particle size of the cellulosic filler is about 20
to about 300 μ .

8. A tablet as claimed in any one of the preceding claims wherein the binding agent is present at about 1 % to about 5 % w/w.
- 5 9. A tablet as claimed in any one of the preceding claims wherein the binding agent is methylcellulose or povidone.
- 10 10. A tablet as claimed in claim 9 wherein the binding agent is povidone.
11. A tablet as claimed in claim 10 wherein the povidone is povidone K90 grade.
- 15 12. A tablet as claimed in any one of the preceding claims wherein the lubricant is present at about 0.1% to about 2.0% w/w.
- 20 13. A tablet as claimed in claim 12 wherein the lubricant is a stearate derivative.
- 25 14. A tablet as claimed in claim 13 wherein the lubricant is magnesium stearate and is present at about 0.1% to about 1.0% w/w.
- 30 15. A tablet as claimed in any one of the preceding claims wherein the valaciclovir or its salt is present at about 65% to about 85% w/w.
- 35 16. A tablet as claimed in any one of the preceding claims comprising valaciclovir hydrochloride.
17. A tablet as claimed in claim 16 wherein the valaciclovir hydrochloride is anhydrous crystalline form including substantially a d spacing pattern as follows:

d spacing pattern (in Angstroms):

5 10.20 \pm 0.08, 8.10 \pm 0.06, 7.27 \pm 0.06, 6.08 \pm
 0.05, 5.83 \pm 0.03, 5.37 \pm 0.02, 5.23 \pm 0.02, 4.89
 \pm 0.02, 4.42 \pm 0.02, 4.06 \pm 0.02, 3.71 \pm 0.02, 3.39
 \pm 0.02, 3.32 \pm 0.02, 2.91 \pm 0.02, 2.77 \pm 0.02.

- 10 18. A tablet as claimed in any one of the preceding
 claims wherein the tapped bulk density of
 valaciclovir or salt thereof is about 0.1 to about
 0.9g/cc.
- 15 19. A tablet as claimed in any one of the preceding
 claims which further includes a disintegrating
 agent present at about 0.5% to about 20% w/w.
- 20 20. A tablet as claimed in claim 19 wherein the
 disintegrating agent is a non-ionic disintegrating
 agent.
21. A tablet as claimed in claim 20 wherein the
 disintegrating agent is crospovidone present at
 about 0.5% to about 7% w/w.
- 25 22. A tablet comprising about 65% to about 85% w/w
 anhydrous crystalline valaciclovir hydrochloride
 including the d spacing diffraction pattern of
 claim 16, about 0.5% to about 5% w/w of povidone,
30 about 3% to about 30% w/w of a cellulosic filler,
 about 0.5 to about 7% w/w of a non-ionic
 disintegrating agent, about 0.1% to about 1.0% of
 a stearate lubricant and about 0.1% to about 0.5%
35 w/w of colloidal silicon dioxide, wherein the
 valaciclovir hydrochloride is present
 intragranularly; and wherein the cellulosic
 filler, stearate lubricant and colloidal silicon

dioxide are present extragranularly.

23. A tablet as claimed in any one of claims 1 to 22 which is film coated.

5

24. A tablet as claimed in any one of the preceding claims for use in medical therapy.

10

25. A method of treatment of a herpes virus infection in a human comprising administering to the host one or more tablets as claimed in any one of the preceding claims to administer an effective anti-herpes viral amount of valaciclovir or a salt thereof.

15

26. A process for preparing a tablet comprising at least about 50% w/w valaciclovir or a salt thereof, a binding agent, a lubricant, and about 0.05 to about 3.0% colloidal silicon dioxide, wherein the friability of the tablet does not exceed 1% the hardness is at least 9 kP and the ejection force does not exceed 1000N; said process having the valaciclovir or its salt present within the granules of the tablet, and the lubricant and colloidal silicon dioxide present extragranularly.

20

25

27. A process for preparing a tablet comprising at least about 50% w/w valaciclovir or a salt thereof, a binding agent, a filler, a lubricant, and about 0.05 to 3.0% w/w colloidal silicon dioxide; wherein the hardness of the tablet is at least 9 kp, the friability is not more than 1%, and the ejection force is not more than 1000N; said process comprising forming granules which include valaciclovir or a salt thereof and then blending the lubricant and colloidal silicon dioxide with

30

35

said granules.

28. A according to claim 26 or 27 comprising forming
granules by mixing said valaciclovir or salt,
optionally a binding agent or a portion thereof,
and optionally the filler or a portion thereof;
granulating with a granulating solution to form
granules or dissolving the binding agent or a
portion in the granulating solution before adding
to valaciclovir; drying the granules; blending the
granules with the lubricant, colloidal silicon
dioxide, and optional filler or a portion thereof;
and then compressing the blended mixture to form a
tablet.
29. A process for preparing a tablet comprising at
least about 50% w/w valaciclovir or a salt thereof,
a binding agent, a lubricant, about 0.05 to about
3% w/w colloidal silicon dioxide, and about 3 to
about 30% w/w of a cellulosic filler; wherein the
hardness of the tablet is at least 9kP, the
friability is not more than 1%, and the ejection
force is not more than 1000N; said process
comprising forming granules by mixing the
valaciclovir or salt, optional binding agent or a
portion thereof, and optionally a portion of
cellulosic filler; granulating with a granulating
solution to form granules or dissolving the binding
agent or a portion thereof in the granulating
solution before adding to valaciclovir; drying the
granules; blending the granules with the lubricant,
colloidal silicon dioxide, and at least a portion
of the cellulosic filler; and then compressing the
blended mixture to form a tablet.






FIG. 2.





INTERNATIONAL SEARCH REPORT

International Publication No
PCT/GB 96/00111

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/20 A61K47/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEMICAL ABSTRACTS, vol. 118, no. 10, 8 March 1993 Columbus, Ohio, US; abstract no. 87553, XP002003233 see abstract & ZHONGGUO YIYAO GONGYE ZAZHI, vol. 23, no. 8, 1992, page 350-1 YUAN, SONGFAN: "Preparation of ibuprofen" ---	1-29
Y	EP,A,0 308 065 (WELLCOME FOUND LTD) 22 March 1989 cited in the application see page 5, line 42 - page 6, line 3 see page 10, line 1 - page 11, line 20 --- -/-	1-29

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 May 1996

Date of mailing of the international search report

29.05.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 EE Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Economou, D

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/GB 96/00111

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEMICAL ABSTRACTS, vol. 69, no. 4, 22 July 1968 Columbus, Ohio, US; abstract no. 11048, XP002003234 see abstract & SB. TR., VSES. NAUCH.-ISSLED. INST. NOV. STROIT. MATER., vol. 15, 1967, page 15-21 EDEL'MAN, L.I.: "Effect of the nature and particle size of fillers and methods for adding components on the hardness of poly(vinyl chloride) compositions."	1-29
Y	CHEMICAL ABSTRACTS, vol. 95, no. 2, 13 July 1981 Columbus, Ohio, US; abstract no. 12656, XP002003235 see abstract & PHARMAZIE, vol. 36, no. 1, 1981, page 32-4 IONCHEV, KH., VELIKOVA, E.: "Optimization of the composition of a multicomponent pharmaceutical form by mathematical investigation designing and experimental testing"	1-29
Y	CHEMICAL ABSTRACTS, vol. 105, no. 16, 20 October 1986 Columbus, Ohio, US; abstract no. 139549, XP002003236 see abstract & FARMATSIYA, vol. 35, no. 4, 1986, page 25-8 STREL'TSOVA ET AL.: "Celanide tablets manufacture by a direct compression method"	1-29
Y	CHEMICAL ABSTRACTS, vol. 102, no. 18, 6 May 1985 Columbus, Ohio, US; abstract no. 154736, XP002003237 see abstract & J. PHARM. PHARMACOL., vol. 37, no. 3, 1985, page 193-5 ESEZOBO, S.: "The effect of some excipients on the physical properties of a paracetamol tablet formulation"	1-29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Publication No

PCT/GB 96/00111

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0308065	22-03-89	AP-A- 55	26-09-89
		AP-A- 160	18-11-91
		AT-T- 116648	15-01-95
		AU-B- 612393	11-07-91
		AU-B- 2097888	16-02-89
		DE-D- 3852682	16-02-95
		DE-T- 3852682	22-06-95
		DK-A- 82694	08-07-94
		DK-B- 170045	08-05-95
		EP-A- 0596542	11-05-94
		ES-T- 2065914	01-03-95
		HK-A- 39595	24-03-95
		JP-A- 1068373	14-03-89
		JP-B- 6062623	17-08-94
		JP-A- 3115284	16-05-91
		JP-B- 7113025	06-12-95
		PT-B- 88261	01-03-95
		SU-A- 1634138	07-03-91
		US-A- 4957924	18-09-90
		US-A- 5061708	29-10-91

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)